Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sickle Cell Disease Orphan Status Lures Pharma Interest

Executive Summary

As interest in drugs with orphan indications picks up and the science advances, sickle cell disease is attracting the attention of big pharma, with deals inked for two promising therapeutics and a variety of approaches in the clinic with partnership potential.

You may also be interested in...

Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness

PGLG's application only has one Phase III trial, and Emmaus is hoping statistical re-analyses can address FDA skepticism about clinical meaningfulness of the primary endpoint data.

Global Blood Therapeutics Inc.

Global Blood Therapeutic Inc.'s homegrown lead candidate is an oral, once-daily drug aimed at sickle cell disease, a genetic condition that causes red blood cells to become deformed or “sickled." The goal with GBT440 is to correct the disease, so that patients would actually have no evidence of it following treatment.

Mast Accelerates Enrollment In Pivotal Sickle Cell Study Of MST-188

With enrollment finally ramping up in trial open to older patients, Mast Therapeutics envisions a broad labeling horizon for MST-188, after a very long development road.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts